» Articles » PMID: 22884354

Tanshinones As Selective and Slow-binding Inhibitors for SARS-CoV Cysteine Proteases

Overview
Journal Bioorg Med Chem
Specialties Biochemistry
Chemistry
Date 2012 Aug 14
PMID 22884354
Citations 121
Authors
Affiliations
Soon will be listed here.
Abstract

In the search for anti-SARS-CoV, tanshinones derived from Salvia miltiorrhiza were found to be specific and selective inhibitors for the SARS-CoV 3CL(pro) and PL(pro), viral cysteine proteases. A literature search for studies involving the seven isolated tanshinone hits showed that at present, none have been identified as coronaviral protease inhibitors. We have identified that all of the isolated tanshinones are good inhibitors of both cysteine proteases. However, their activity was slightly affected by subtle changes in structure and targeting enzymes. All isolated compounds (1-7) act as time dependent inhibitors of PL(pro), but no improved inhibition was observed following preincubation with the 3CL(pro). In a detail kinetic mechanism study, all of the tanshinones except rosmariquinone (7) were identified as noncompetitive enzyme isomerization inhibitors. However, rosmariquinone (7) showed a different kinetic mechanism through mixed-type simple reversible slow-binding inhibition. Furthermore, tanshinone I (5) exhibited the most potent nanomolar level inhibitory activity toward deubiquitinating (IC(50)=0.7 μM). Additionally, the inhibition is selective because these compounds do not exert significant inhibitory effects against other proteases including chymotrysin, papain, and HIV protease. These findings provide potential inhibitors for SARS-CoV viral infection and replication.

Citing Articles

Proteins and DNA Sequences Interacting with Tanshinones and Tanshinone Derivatives.

Szymczyk P, Majewska M, Nowak J Int J Mol Sci. 2025; 26(2).

PMID: 39859562 PMC: 11765770. DOI: 10.3390/ijms26020848.


Effect of Co-Solvents, Modified Starch and Physical Parameters on the Solubility and Release Rate of Cryptotanshinone from Alcohologels.

Kobryn J, Demski P, Raszewski B, Zieba T, Musial W Molecules. 2025; 29(24.

PMID: 39769966 PMC: 11678525. DOI: 10.3390/molecules29245877.


Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update.

Mia M, Howlader M, Akter F, Hossain M Clin Pathol. 2024; 17:2632010X241263054.

PMID: 39070952 PMC: 11282570. DOI: 10.1177/2632010X241263054.


Exploring the potential mechanisms of Danshen against COVID-19 via network pharmacology analysis and molecular docking.

Zhang Q, Liang Z, Wang X, Zhang S, Yang Z Sci Rep. 2024; 14(1):12780.

PMID: 38834599 PMC: 11150561. DOI: 10.1038/s41598-024-62363-x.


Pseudovirus-Based Systems for Screening Natural Antiviral Agents: A Comprehensive Review.

Trischitta P, Tamburello M, Venuti A, Pennisi R Int J Mol Sci. 2024; 25(10).

PMID: 38791226 PMC: 11121416. DOI: 10.3390/ijms25105188.


References
1.
Devaraj S, Wang N, Chen Z, Chen Z, Tseng M, Barretto N . Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem. 2007; 282(44):32208-21. PMC: 2756044. DOI: 10.1074/jbc.M704870200. View

2.
Li S, Lai C, Ping J, Tsai F, Wan L, Lin Y . Severe acute respiratory syndrome coronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways. J Gen Virol. 2011; 92(Pt 5):1127-1140. DOI: 10.1099/vir.0.028936-0. View

3.
Ghosh A, Takayama J, Aubin Y, Ratia K, Chaudhuri R, Baez Y . Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. J Med Chem. 2009; 52(16):5228-40. PMC: 3148848. DOI: 10.1021/jm900611t. View

4.
De Clercq E . Antiviral drugs in current clinical use. J Clin Virol. 2004; 30(2):115-33. DOI: 10.1016/j.jcv.2004.02.009. View

5.
Wu C, Jan J, Ma S, Kuo C, Juan H, Cheng Y . Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004; 101(27):10012-7. PMC: 454157. DOI: 10.1073/pnas.0403596101. View